Criteria for severity of prostatic hyperplasia and the treatment efficacy
Masumori, N.; Tsukamoto, T.
Nihon Rinsho. Japanese Journal of Clinical Medicine 60(Suppl 11): 322-326
2002
ISSN/ISBN: 0047-1852 PMID: 12599593 Document Number: 541208
Document emailed within 1 workday
Related Documents
Sivkov, A.V.; Egorov, A.A.; Romikh, V.V.; Surikov, V.N. 2002: Urodynamic criteria of predicting efficacy of therapy with alpha1-adrenergic blockaders in patients with benign prostatic hyperplasia Urologiia 2002(5 Suppl): 13-22Granados Loarca, E.A. 1999: Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume Archivos Espanoles de Urologia 52(3): 201-208
Wu, T.T.; Lee, Y.H.; Jiaan, B.P.; Huang, J.K. 1995: The efficacy of finasteride in the treatment of symptomatic benign prostatic hyperplasia Zhonghua Yi Xue Za Zhi 56(6): 399-403
Li, Y.-Z.; Liang, W.-N.; Zhang, G.-W.; Weng, Z.-Q.; Zhong, Y.; Xu, S.; Shang, X.-J. 2019: Efficacy and safety of lycopene in the treatment of benign prostatic hyperplasia with lower urinary tract symptoms Zhonghua Nan Ke Xue 25(11): 1001-1004
Anwarul Islam, A.K.M.; Kashem, M.A.; Shameem, I.A.; Kibria, S.A.M.G. 2005: Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: a comparative study Bangladesh Medical Research Council Bulletin 31(2): 54-61
Bogdanowicz, J.F.; Bentvelsen, F.M.; Oosterom, R.; Schroeder, F.H. 1991: Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia Scandinavian Journal of Urology and Nephrology. Supplementum 138: 97-103
Buzelin, J.M.; Roth, S.; Geffriaud-Ricouard, C.; Delauche-Cavallier, M.C. 1997: Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group European Urology 31(2): 190-198
Aliaev, I.G.; Vinarov, A.Z.; Demidko, I.L.; Spivak, L.G. 2013: The results of the 10-year study of efficacy and safety of Serenoa repens extract in patients at risk of progression of benign prostatic hyperplasia Urologiia 4: 32-36
Kongkanand, A.; Chodchoy, V.; Lojanapiwat, B.; Pumpaisanchai, S.; Ratana-Olarn, K.; Sae-Tang, P.; Taweemonkongsap, T. 2009: Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia Journal of the Medical Association of Thailand 92(7): 969-978
Jonas, U.; Melchior, H.; Rübben, H. 1998: Recommendations for billing alternative therapy of benign prostatic hyperplasia. Laser therapy of benign prostatic hyperplasia Der Urologe. Ausg. a 37(1): 110-111
McConnell, J.D. 1995: Benign prostatic hyperplasia. Hormonal treatment Urologic Clinics of North America 22(2): 387-400
Kumanov, H.; Mladenov, D.; Nikolov, S.; Penkov, R.; Stratev, S.; Kotzev, R.; Petkova, L.; Ganev, T.; Uzunov, A.; Uzunov, N. 1998: Treatment of benign prostatic hyperplasia with tamsulosin Khirurgiia 53(6): 38-41
Gorilovskiĭ, L.M. 1995: Permixon in the treatment of benign prostatic hyperplasia Terapevticheskii Arkhiv 67(8): 62-64
Ekman, P.; Andersen, J.T.; Wolf, H. 1996: Finasteride in the treatment of benign prostatic hyperplasia Acta Urologica Belgica 64(1): IX-XII
Chepurov, A.K. 1999: Holmium laser treatment of benign prostatic hyperplasia Urologiia 4: 39-41
Lepor, H. 1995: Alpha blockade for the treatment of benign prostatic hyperplasia Urologic Clinics of North America 22(2): 375-386
Moon, L.; Pfettscher, S. 1995: Hytrin treatment of hypertension and benign prostatic hyperplasia Anna Journal 22(3): 335-336
Ustinov, D.V.; Kholtobin, D.P.; Kul'chavenia, E.V.; Aĭzikovich, B.I. 2013: The use of laser vaporization for the treatment of benign prostatic hyperplasia Urologiia 4: 74
Kupriyanov, Y.A.; Rasner, P.I.; Rokhlikov, I.M.; Akrikidi, A.A.; Soloviev, V.V.; Markov, A.A.; Nozdrin, E.V.; Logvinov, L.A.; Vasilevskiy, R.P.; Skrupskiy, K.S.; Pushkar, D.Y.; Putilovskiy, M.A.; Epstein, O.I. 2019: The experience of using drug Afalaza for treatment of lower urinary symptoms in treatment-nave patients with benign prostatic hyperplasia Urologiia 3: 36-42
Brannen, G.E.; Coffey, D.S. 1977: Tumor-specific immunity in patients with prostatic adenocarcinoma or benign prostatic hyperplasia Cancer Treatment Reports 61(2): 211-216